Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas (Nasdaq: ARVN) announced that Randy Teel, Ph.D., has been appointed President, Chief Executive Officer, and director effective February 12, 2026. Teel succeeds John Houston, Ph.D., who is retiring as CEO and chair but will remain a board member and provide consulting services. Briggs Morrison, M.D., becomes board chair.
The release highlights Teel’s 20 years of industry experience, his role in Arvinas’ 2018 IPO, the company’s first positive pivotal PROTAC trial, demonstrated CNS pharmacodynamic activity, and over $2 billion raised through financings and partnerships.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Arvinas (NASDAQ: ARVN) presented preclinical data showing enhanced antitumor activity when its PROTAC BCL6 degrader ARV-393 is combined with glofitamab (CD20×CD3) at ASH 2025.
Key findings: concomitant ARV-393 (3 mg/kg) + glofitamab (0.15 mg/kg) produced 81% tumor growth inhibition (TGI) and sequential dosing produced 91% TGI vs 38% and 36% for each agent alone; higher-dose ARV-393 (6 mg/kg) combinations yielded markedly higher tumor regressions (10/10 and 7/8 mice vs 5/11 and 0/11 for single agents). RNA sequencing showed CD20 upregulation and increased interferon/antigen-presentation gene expression. Arvinas plans to initiate a Phase 1 combination cohort in DLBCL in 2026.
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Arvinas (Nasdaq: ARVN) announced multiple abstracts on vepdegestrant (ARV-471) accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025 in San Antonio, TX.
Presentations include subgroup analyses from the phase 3 VERITAC-2 trial versus fulvestrant, ctDNA biomarker analyses from a phase 1/2 study, real-world ESR1 mutation prevalence after 1L therapy, an I-SPY2 endocrine optimization pilot, and a phase 1/2 trial of PF-07248144 combined with vepdegestrant. Pfizer is a development collaborator and Quantum Leap sponsors I-SPY2 EOP. Full abstracts available via the SABCS online program.
Arvinas (NASDAQ: ARVN) reported 3Q2025 results and a corporate update highlighting clinical and preclinical progress, collaboration milestones, and financial positions. Key clinical highlights include ARV-102 showing >90% PBMC LRRK2 reduction and >50% CSF reduction with brain penetration, and ARV-102 effects on distal CSF biomarkers; ARV-806 preclinical potency ~25x–40x versus competitors with >90% degradation for 7 days in models; ARV-027 demonstrated 40–60% muscle polyQ-AR reduction and functional benefit in SBMA mice. Regulatory/commercial: FDA accepted the NDA for vepdegestrant with a PDUFA date of June 5, 2026 and Arvinas/Pfizer will jointly select a commercialization partner. Cash was $787.6M at Sept 30, 2025, funding operations into H2 2028 per management.
Arvinas (NASDAQ: ARVN) will present preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab at the 2025 American Society of Hematology (ASH) Annual Meeting.
The poster (Publication No. 1520) is in Session 605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, on December 6, 2025, 5:30 PM–7:30 PM ET, at OCCC – West Halls B3–B4. The full abstract is available via the ASH online program.
Arvinas (Nasdaq: ARVN) said management will participate in two investor conferences in November 2025: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and the Jefferies London Healthcare Conference on Tuesday, November 18, 2025.
Both presentations will offer a live audio webcast accessible via links and the company’s Events and Presentations web section.
Arvinas (Nasdaq: ARVN) will report third quarter 2025 financial results and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET.
Management will review the company's Q3 2025 financial results and deliver a corporate update. The live webcast is accessible under “Events and Presentations” on Arvinas' investor website and a replay will be available at www.arvinas.com after the event.
Arvinas (Nasdaq: ARVN) announced preclinical data for ARV-806, a PROTAC KRAS G12D degrader, presented Oct 24, 2025 at the AACR-NCI-EORTC conference.
Key points: picomolar in vitro KRAS G12D degradation across pancreatic, colorectal and lung lines; >25-fold greater antiproliferative potency versus clinical-stage G12D inhibitors; >40-fold higher KRAS G12D degradation potency versus a clinical-stage G12D degrader; single IV dose produced >90% KRAS G12D degradation for seven days with c-MYC suppression and BIM induction for ≥5 days; ≥30% tumor volume reductions in pancreatic, colorectal CDX and a lung PDX model. ARV-806 is in a Phase 1 trial (NCT07023731).